FibroBiologics, Inc. Common Stock (FBLG)vsNovartis AG ADR (NVS)
FBLG
FibroBiologics, Inc. Common Stock
$1.32
+0.76%
HEALTHCARE · Cap: $6.45M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
FBLG
Avoid23
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for FBLG.
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : FBLG
The strongest argument for FBLG centers on Price/Book.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : FBLG
The primary concerns for FBLG are Revenue Growth, EPS Growth, Market Cap. Debt-to-equity of 56.90 is elevated, increasing financial risk.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
FBLG profiles as a value stock while NVS is a declining play — different risk/reward profiles.
FBLG carries more volatility with a beta of 1.10 — expect wider price swings.
FBLG is growing revenue faster at 0.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 23/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
FibroBiologics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
FibroBiologics, Inc. is a leading biotechnology company at the forefront of regenerative medicine, specializing in the innovative application of fibroblast cells to address degenerative diseases and spinal disorders. With a solid intellectual property portfolio, the company is well-positioned in the competitive cellular therapy market, emphasizing clinical innovation and excellence. Through strategic collaborations and active research efforts, FibroBiologics is committed to revolutionizing healthcare and improving patient outcomes with its groundbreaking therapeutic products.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?